SPAS(SH:603168) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-09-03 23:06Group 1 - The core point of the announcement is that Zhejiang Shapuaisi Pharmaceutical Co., Ltd.'s wholly-owned subsidiary has received approval for clinical trials of a new eye drop medication, which is intended for the treatment of presbyopia in adults [1][2]. - The drug, named Pilocarpine Hydrochloride Eye Drops, is classified as a Class 3 chemical drug and is currently in the clinical trial phase [1][3]. - The total research and development investment for the Pilocarpine Hydrochloride Eye Drops project has reached approximately 6.4457 million RMB [3]. Group 2 - The major shareholder, Mr. Chen Dekang, holds 43,871,004 shares, accounting for 11.67% of the total share capital of the company [7]. - Mr. Chen plans to reduce his holdings by up to 3,759,250 shares through centralized bidding and another 3,759,250 shares through block trading, totaling a maximum of 7,518,500 shares, which is 2.00% of the total share capital [7][8]. - The reduction plan is due to personal financial needs and will take place from September 25, 2025, to December 24, 2025 [7].